PRA Named International Clinical Research Company of the Year
May 24 2018 - 4:00AM
RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) --
PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it
was recognized by PharmaTimes as the International
Clinical Research Company of the Year. This is the fifth year in a
row that PRA has received this award.
"This award celebrates excellence in the clinical
research industry and we are honored to once again be recognized by
our peers," said Colin Shannon, President and Chief Executive
Officer. "This award is possible thanks to the incredibly talented
PRA team members we have working around the world who are deeply
committed to their work in bringing new and life-saving therapies
to the patients who need them."
PRA also swept the Clinical Research Associate and
Clinical Trial Administrator categories capturing a total of 11
awards. These awards follow PRA's recognition earlier this month in
the PharmaTimes Americas competition where PRA also received 11
awards, including Company of the Year.
The PharmaTimes, International Clinical Researcher
of the Year competition is designed to challenge, recognize, and
reward the talent and passion of industry and academic researchers.
Comprised of three stages, the competition offers professionals in
the clinical research industry an opportunity to benchmark their
skills against their peers in a learning environment and have them
judged by an independent executive steering group of industry
leaders.
ABOUT PRA HEALTH
SCIENCES
PRA is one of the world's leading global contract
research organizations, by revenue, providing outsourced clinical
development services to the biotechnology and pharmaceutical
industries. PRA's global clinical development platform includes
More than 70 offices across North America, Europe, Asia, Latin
America, South Africa, Australia and the Middle East, and over
15,800 employees worldwide. Since 2000, PRA has participated in
approximately 3,700 clinical trials worldwide. In addition, PRA has
participated in the pivotal or supportive trials that led to U.S.
Food and Drug Administration or international regulatory approval
of more than 75 drugs. To learn more about PRA, please
visit www.prahs.com.
Media Inquiries: Christine Rogers, Director,
Public Relations, Corporate
Communications rogerschristine@prahs.com
A photo accompanying this announcement is
available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/075c9112-9b1d-4a83-a1f4-ae65e378cd9f
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: PRA Health Sciences via Globenewswire
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Oct 2023 to Oct 2024